Revive Therapeutics (TSE:RVV) has released an update.
Revive Therapeutics has secured a Type C meeting with the FDA to discuss a clinical study for treating long COVID with their drug Bucillamine, which has shown promise in preliminary analyses. The economic impact of long COVID is substantial, with estimates reaching $3.7 trillion, highlighting the urgency for effective treatments. The company, known for its focus on infectious diseases and rare disorders, is leveraging previous Phase 3 trial data to advance Bucillamine’s development.
For further insights into TSE:RVV stock, check out TipRanks’ Stock Analysis page.
